CRDF
Cardiff Oncology Inc

18,802
Mkt Cap
$130.58M
Volume
1.22M
52W High
$4.56
52W Low
$1.48
PE Ratio
-2.78
CRDF Fundamentals
Price
$1.96
Prev Close
$1.91
Open
$1.96
50D MA
$2.33
Beta
1.45
Avg. Volume
1.84M
EPS (Annual)
-$0.6864
P/B
2.87
Rev/Employee
$19,129.03
$130.35
Loading...
Loading...
News
all
press releases
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price
Piper Sandler reduced their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·1d ago
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18...
MarketBeat·2d ago
News Placeholder
Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday
Cardiff Oncology (NASDAQ:CRDF) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat...
MarketBeat·21d ago
News Placeholder
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at Zacks Small Cap lifted their FY2027 earnings estimates for Cardiff Oncology in a report issued on Tuesday, February...
MarketBeat·22d ago
News Placeholder
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF)
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors bought 2,705 call options on the company. This represents an...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study
Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004...
MarketBeat·1mo ago
News Placeholder
Q4 Earnings Estimate for CRDF Issued By Noble Financial
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at Noble Financial issued their Q4 2025 earnings per share estimates for Cardiff Oncology in a research report issued to clients and...
MarketBeat·2mo ago
News Placeholder
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF)
Noble Financial started coverage on Cardiff Oncology in a research report on Monday. They issued an "outperform" rating and a $12.00 price objective for the company...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRDF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.